Replimune Secures $200 Million In Non-Dilutive Debt Financing From Hercules Capital, Inc.
Amount Raised
$200 Million
Round Type
Debt Financing
WoburnBiotechnologyHealth CareDescription
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that it has obtained a $200 million non-dilutive term loan facility from Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. This non-dilutive capital extends cash runway into 2025 ahead of key catalysts from the Company’s registration-directed CERPASS and IGNYTE trials in cutaneous squamous cell carcinoma (CSCC) and anti-PD1 failed melanoma inclusive of the costs of funding commercial infrastructure and the running of a confirmatory study to support a potential BLA filing in anti-PD1 failed melanoma.
Who to call at Replimune, and when
A new round usually means Replimune is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Replimune raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Replimune, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Replimune. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Replimune raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Replimune raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.